Discontinued drugs in 2006: renal, endocrine and metabolic drugs

Abstract

This perspective summarizes key compounds from the endocrine and metabolic area that were discontinued from clinical development during the calendar year 2006. This is a continuation in a series of perspectives of each of the editorial areas summarized by Expert Opinion on Investigational Drugs. The candidates covered in this summary were being developed for the treatment of diabetes and obesity, as well as for reproductive and urogenital health issues.

Keywords::

• diabetes
• obesity
• tesaglitazar
• muraglitazar
• discontinued drugs

Disclosure

J Colca is President and Founder of Metabolic Solutions Development Co. and Kalamazoo Metabolic Research.